Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia*

American Journal of Cardiology

Volumn 89, Issue 6, 2002, Pages 672-678

  Kashyap, Moti L ^a   McGovern, Mark E ^b   Berra, Kathleen ^c   Guyton, John R ^d   Kwiterovich Jr , Peter O ^e   Harper, Wayne L ^f   Toth, Phillip D ^g   Favrot, Laurence K ^h   Kerzner, Boris ⁱ   Nash, Stephen D ^j   Bays, Harold E ^k   Simmons, Phillip D ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b Kos Pharmaceuticals   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f WAKE RESEARCH ASSOCIATES   (United States)

^g Midwest Institute for Clinical Research   (United States)

^h San Diego Cardiac Center   (United States)

ⁱ Health Trends Research   (United States)

^j Cholesterol Control Center   (United States)

^k LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FLUSHING; HEADACHE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RASH; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); LOVASTATIN; MALE; MIDDLE AGED; NIACIN; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037086184     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02338-4     Document Type: Article

References (27)

1. The benefits of niacin in atherosclerosis
2. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
3. Contrasting effects of unmodified and time-release forms of niacin on lipoprotein in hyperlipidemic subjects: Clues to mechanism of action of niacin
4. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
5. Regulatory concerns at various phases of drug development
6. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
7. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells
8. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport
9. Mechanism of action of niacin on lipoprotein metabolism
10. Statin-induced inhibition of the Rho-signaling pathway actives PPAR α and induces HDL apoA-I
11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
12. Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial
13. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
14. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
15. Treatment of hyperlipidemia with combined niacin-statin regimens
16. Lipoprotein (a), and coronary heart disease. Meta-analysis of prospective studies
17. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
18. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. Long-term effects of pravastatin on plasma concentration of C-reactive protein
20. Clofibrate and niacin in coronary heart disease
21. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
22. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
24. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)
25. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography
26. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
27. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts